-
公开(公告)号：KR101485178B1
公开(公告)日：2015-01-26
申请号：KR1020130012262
申请日：2013-02-04
Applicant: 한국식품연구원 , 호서대학교 산학협력단
Abstract: 본 발명은 삶은 콩에
B.
licheniformis 를 접종하여 발효시킨 청국장 또는 그의 추출물을 유효성분으로 함유하는 치매의 예방 및 치료용 약학 조성물을 제공한다.-
公开(公告)号：KR1020140099971A
公开(公告)日：2014-08-14
申请号：KR1020130012262
申请日：2013-02-04
Applicant: 한국식품연구원 , 호서대학교 산학협력단
CPC classification number: A61K36/48 , A23L11/09 , A23V2200/322 , A61K2236/19 , C12P1/04
Abstract: The present invention provides a pharmaceutical composition comprising bean paste fermented by inoculating licheniformis to boiled beans or an extract thereof as an active ingredient for preventing and treating dementia. The fermented bean paste according to the present invention prevents accumulation of β-amyloid in the hippocampal CA1 region and has effects of alleviating cognitive impairments of a dementia animal model and anti-dementia effect, thereby can be usefully used as a composition for preventing and treating dementia.
Abstract translation: 本发明提供一种药物组合物，其包含通过将地衣芽孢菌接种至煮沸豆或其提取物发酵的豆酱作为预防和治疗痴呆的活性成分。 根据本发明的发酵豆酱防止β-淀粉样蛋白在海马CA1区域中的积累，并且具有减轻痴呆动物模型的认知障碍和抗痴呆作用的作用，因此可以有效地用作预防和治疗组合物 痴呆。
-
公开(公告)号：KR1020140086213A
公开(公告)日：2014-07-08
申请号：KR1020120156419
申请日：2012-12-28
Applicant: 한국식품연구원
IPC: A61K31/519 , A61K31/407 , A61P3/04
CPC classification number: A61K31/519 , A23L33/10 , A61K31/407 , Y10S514/866 , Y10S514/886
Abstract: The present invention relates to a composition for treating obesity-induced inflammation, wherein the composition contains evodiamine as an active ingredient. The composition of the present invention induces the expression of adiponectin and decreases the expression of IL-6 and MCP-1 which are involved in obesity-mediated inflammation reaction so that obesity-induced inflammation can be prevented and treated.
Abstract translation: 本发明涉及一种用于治疗肥胖症的炎症的组合物，其中该组合物含有作为活性成分的吴茱萸碱。 本发明的组合物诱导脂联素的表达并降低参与肥胖介导的炎症反应的IL-6和MCP-1的表达，从而可以预防和治疗肥胖诱发的炎症。
-
公开(公告)号：KR1020140086210A
公开(公告)日：2014-07-08
申请号：KR1020120156408
申请日：2012-12-28
Applicant: 한국식품연구원
IPC: A61K31/47 , A61K31/435 , A61P3/04 , A61P29/00
CPC classification number: A61K31/4741 , A23L33/10 , A61K31/4748 , Y10S514/866 , Y10S514/886 , Y10S514/909
Abstract: The present invention relates to a composition for treating obesity-induced inflammation, wherein the composition contains tetrandrine as an active ingredient. The composition of the present invention induces the expression of adiponectin and decreases the expression of IL-6 and MCP-1 which are involved in obesity-mediated inflammation reaction so that obesity-induced inflammation can be prevented and treated.
Abstract translation: 本发明涉及一种用于治疗肥胖症引起的炎症的组合物，其中该组合物含有四片丹宁作为活性成分。 本发明的组合物诱导脂联素的表达并降低参与肥胖介导的炎症反应的IL-6和MCP-1的表达，从而可以预防和治疗肥胖诱发的炎症。
-
公开(公告)号：KR1020140006376A
公开(公告)日：2014-01-16
申请号：KR1020120073081
申请日：2012-07-04
Applicant: 한국식품연구원
IPC: A61K31/404 , A61K31/4025 , A61P35/00 , A61P25/28
CPC classification number: A61K31/404 , A23L29/045 , A61K9/0095 , A61K9/08 , A61K9/10 , A61K9/14 , A61K9/20 , A61K9/48 , Y10S514/886
Abstract: The present invention relates to a pharmaceutical composition containing 3,3'-Diindolymethane as an active ingredient for preventing and treating inflammatory diseases and angiogenesis inhibitory activity. According to the present invention, the 3,3'-Diindolymethane has an excellent effect in inhibiting angiogenesis and inflammation, thereby being used as the active ingredient in the pharmaceutical composition and health functional food for preventing and treating inflammatory diseases. [Reference numerals] (AA,EE,II,MM) Normal group; (BB,FF,JJ,NN) Control group; (CC,GG,KK,OO) Experimental group 1; (DD,HH,LL,PP) Experimental group 2
Abstract translation: 本发明涉及含有3,3'-二取代甲烷作为预防和治疗炎性疾病和血管生成抑制活性的活性成分的药物组合物。 根据本发明，3,3'-二聚甲烷在抑制血管发生和炎症中具有优异的效果，因此用作用于预防和治疗炎性疾病的药物组合物和保健功能食品中的活性成分。 （标号）（AA，EE，II，MM）正常组; （BB，FF，JJ，NN）对照组; （CC，GG，KK，OO）实验组1; （DD，HH，LL，PP）实验组2
-
Patent Agency Ranking
公开(公告)号：KR101327938B1
公开(公告)日：2013-11-14
申请号：KR1020110037694
申请日：2011-04-22
Applicant: 한국식품연구원
IPC: A61K31/215 , A61K31/21 , A61K9/48 , A61P3/04
Abstract: 본 발명은 메틸 카페이트를 유효성분으로 함유하는 비만 및 지질 관련 대사성 질환의 예방 및 치료용 약학적 조성물과 건강기능식품에 관한 것이다. 상기 조성물 또는 건강기능식품은 지방세포분화 저해 효능이 우수하다.
-
公开(公告)号：KR1020130098759A
公开(公告)日：2013-09-05
申请号：KR1020120020537
申请日：2012-02-28
Applicant: 한국식품연구원
CPC classification number: Y02A90/26
Abstract: PURPOSE: A method for diagnosing aging is provided to diagnose aging and related diseases by measuring a change in the concentration of a specific metabolite in a liver extract and to treat aging-related diseases. CONSTITUTION: A method for diagnosing aging comprises the steps of: measuring the concentration of one selected among a metabolite group including 3-methylglutarylcarnitine, isovalerylcarnitine, palmitoylcarnitine, iobutyrylcarnitine, hypoxanthine, patothenic acid, lysophosphatidylcholine(C18:0) and lysophosphatidylcholine(C22:6); measuring the concentration of one selected among the metabolite group; and determining aging when the primarily measured concentration is higher than the secondarily measured concentration.
Abstract translation: 目的：通过测量肝脏提取物中特定代谢物浓度的变化和治疗老化相关疾病，提供诊断衰老的方法诊断衰老及相关疾病。 构成：用于诊断老化的方法包括以下步骤：测量选自包括3-甲基戊二酰肉碱，异戊基肉毒碱，棕榈酰肉碱，异丁酸肉碱，次黄嘌呤，氨基苯甲酸，溶血磷脂酰胆碱（C18：0）和溶血磷脂酰胆碱（C22：6） ）; 测定代谢组中选出的1种浓度; 并且当主要测量的浓度高于二次测量的浓度时，确定老化。
-
18.发明公开
公开(公告)号：KR1020120061018A
公开(公告)日：2012-06-12
申请号：KR1020100109058
申请日：2010-11-04
Applicant: 한국식품연구원
Abstract: PURPOSE: A pharmaceutical composition and health functional food containing p-xyleneselenocyanate are provided to prevent and treat obesity and lipid-related metabolic disorders. CONSTITUTION: A pharmaceutical composition for preventing and treating obesity and lipid-related metabolic disorders contains 0.1-50 wt% of p-xylene selenocyanate as an active ingreedient. The metabolic diseases include diabetes, hyperlipidemia, fatty liver, artheriosclerosis, hypertension, cardiovascular diseases, or a combination thereof. The composition is manufactured in the form of powder, granules, tablets, capsules, suspension, emulsion, syrup, oral formulation of aerosol, external use formulation, suppository, or sterilized injection solution. A health functional food for preventing and relieving obesity and lipid-related metabolic disorders contains p-xylene selenocyanate as an active ingredient.
Abstract translation: 目的：提供含有对二甲苯硒异氰酸酯的药物组合物和保健功能食品，用于预防和治疗肥胖症和与脂质有关的代谢紊乱。 构成：用于预防和治疗肥胖症和与脂质有关的代谢紊乱的药物组合物含有0.1-50重量％的对二甲苯硒氰酸酯作为活性成分。 代谢疾病包括糖尿病，高脂血症，脂肪肝，神经硬化，高血压，心血管疾病或其组合。 组合物以粉末，颗粒，片剂，胶囊，悬浮液，乳剂，糖浆，气雾剂口服制剂，外用制剂，栓剂或灭菌注射液的形式制造。 用于预防和减轻肥胖症和与脂质有关的代谢紊乱的健康功能食品含有对二甲苯硒氰酸酯作为活性成分。
-
公开(公告)号：KR1020120003779A
公开(公告)日：2012-01-11
申请号：KR1020100064564
申请日：2010-07-05
Applicant: 한국식품연구원
IPC: A61K36/185 , A61P3/04 , A61P3/00
Abstract: PURPOSE: A composition containing Pittosporum heterophyllum extract for preventing or treating obesity is provided to suppress differentiation of adipocytes and to activate AMPK(5'AMP-activated protein kinase). CONSTITUTION: A composition for preventing and treating obesity contains 0.1-99.9 wt% of Pittosporum heterophyllum extract as an active ingredient. The composition is a pharmaceutical composition or food additive composition. A food composition for preventing and treating obesity contains Pittosporum heterophyllum extract as an active ingredient. The composition is manufactured in the form of a pill, powder, granule, tablet, capsule, or beverage.
Abstract translation: 目的：提供含有用于预防或治疗肥胖症的Pittosporum heterophyllum提取物的组合物，以抑制脂肪细胞的分化并激活AMPK（5'AMP激活的蛋白激酶）。 构成：用于预防和治疗肥胖症的组合物含有0.1-99.9重量％的作为活性成分的Pittosporum heterophyllum提取物。 该组合物是药物组合物或食品添加剂组合物。 用于预防和治疗肥胖症的食物组合物含有作为活性成分的孔雀虱提取物。 组合物以丸剂，粉剂，颗粒剂，片剂，胶囊剂或饮料的形式制备。
-
公开(公告)号：KR102085669B1
公开(公告)日：2020-03-06
申请号：KR1020190000225
申请日：2019-01-02
Applicant: 한국 한의학 연구원 , 한국식품연구원
IPC: C12Q1/6883
-
-
-
-
-
-
-
-
-
Search Results
56
records
(took 0.028 seconds)
